Transforming cannabis into scientifically proven and clinically approved medical solutions

OWC Pharmaceutical Research Corp. realizes the potential of medical cannabis research and develops pharmaceutical products, specifically designed to improve the lives of millions.

Through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., the company conducts medical research and clinical trials to develop cannabis-based novel therapeutic products and treatments, and develops unique and effective delivery systems and dosage forms of medical cannabis for diverse medical conditions including multiple myeloma, psoriasis, fibromyalgia and PTSD.

The company’s research is conducted at the facilities of leading Israeli academic medical centers and scientific institutes, and is led by internationally renowned investigators.

Our multi-disciplinary team of experts delivers years of proven experience in medical science and regulatory affairs, as well as extensive experience in diverse cannabis-related topics.

OWCP’s Intellectual Property Portfolio comprises the following:

  • 9 patent families
  • 31 patent filings in selected domains at various stages from PCT filings, National Phase filings and Continuations in Part (CIPs)
  • 3 granted patents in the USA, Australia and Czech Republic
  • 2 of the patent families are in the field of Multiple Myeloma
  • 7 patent families are in the fields of pharmaceutical
    emulsions, Fibromyalgia, Migraine, Sexual Function and
    Skin Disorders

OWC Pharmaceutical Research is traded on the OTCQB market –
symbol OWCP.

Close Menu